Immatics today announced the appointment of Thomas Ulmer as Chief Financial Officer, effective April 1st, 2018. Thomas Ulmer joins Immatics from the Merck Group, where he is currently Chief Financial Officer of the Allergopharma Business Unit.
by eazee-designstudio
Themis announced the close of a Series C financing round led by Global Health Investment Fund (GHIF) as a new investor in the company. Glenn Rockman, Partner at GHIF, will join Themis’ Supervisory Board. The Series C proceeds will be used to advance Themis’ clinical and pre-clinical vaccine development programs.
Today, Ambu A/S – a leader in the development, manufacture and marketing of single-use devices for hospitals – has agreed to acquire invendo medical GmbH for a purchase price of up to EUR 225m. invendo medical is a leading developer of sterile, single-use HD endoscopy products in the field of gastroenterology and gastrointestinal surgery.
Immatics today announced the completion of its Series E financing, raising $58 million.
Immatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program.
MSD today announced the acquisition of Rigontec for up to US$553M
The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom's innovation agency, Innovate UK. Themis will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate.
Immatics today announced that it has initiated enrolment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA101 phase I trial is the first industry-sponsored trial using products consisting of autologous cytotoxic T lymphocytes targeting defined tumor antigens using Immatics’ novel and proprietary target warehouse.
A promising prophylactic vaccine candidate against Chikungunya fever will be tested from August on in a Phase II clinical study in Puerto Rico, a Chikungunya fever endemic area.
4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208.